Summary. Glibenclamide enhanced the activity in the rat of guanylate cyclase in a number of extra-pancreatic tissues. Thus, glibenclamide enhanced guanylate cyclase activity in vitro two-to threefold in liver, kidney, heart, spleen and colon at a concentration of 1 ~tmol/1. Dose-response curves of glibenclamide on hepatic guanylate cyclase revealed that more than half-maximal stimulation was observed at a concentration as low as 10 nmol/l (p < 0.001) and no stimulation of guanylate cyclase was seen when the concentration was decreased to 1 nmol/l. Maximal enhancement was seen at 100 nmol/1 of glibenclamide. Varying the concentration of the guanylate cyclase co-factor manganese had no effect on the glibenclamide enhancement of guanylate cyclase. In addition to the increased insulin receptors found recently in monocytes and fibroblasts, the present findings may help explain the extra-pancreatic effects of glibenclamide and possibly of other sulphonylurea drugs.
Glibenclamide has been reported to be 1000 times more effective than tolbutamide in man [1] . Glibenclamide has effects on both the pancreas [24] and extra-pancreatic tissues [5, 6] , but its mechanisms of action have not been completely elucidated. Clinical studies have suggested that glibenclamide may improve diabetic control and improve glucose tolerance through a mechanism other than increased insulin secretion [7, 8] . In the peripheral tissues of diabetic animals, insulin enhances the activity of guanylate cyclase (E. C. 4.6.1.2), the enzyme that catalyzes the production of cyclic GMP [9] . The present investigation was designed to determine if glibenclamide, like insulin, might have a direct effect on extra-pancreatic guanylate cyclase activity.
Materials and Methods

Animals
Tissues used in these experiments were obtained fi'om male Sprague-Dawley rats weighing 150-200 g. These animals had been maintained on Purina laboratory chow and tap water ad libitum.
Materials
Glibenclamide (glyburide) was dissolved immediately before use in triple-distilled water to make the concentrations specified below. Alumina, neutral activity I for the column chromatography, was obtained from Merck, Darmstadt, FGR. The [a32p]-guanosine triphosphate was from International Chemical and Nuclear Corporation, Irvine, California, USA.
Guanylate Cyclase Assay
Guanylate cyclase activity was measured as described previously [9, 10] . The various tissues were homogenized in cold 0.03 tool/1 Tris HC1 (pH 7.6) and then centrifuged at 37,000 x g at 4 ~ for 15 min. When centrifuged at 37,000 x g, over 95% of guanylate cyclase activity was in the supernatant. The supernatant, to which glibenclamide had been added to obtain the final concentrations noted in the text, was then assayed at 37 o C for 10 min for guanylate cyclase activity. The reaction mixture contained final concentrations of Tris HCI 20 mmol/l, pH 7.6; MnC12 4 mmol/1; cyclic GMP 2.67 mmol/1 (used to minimize destruction of [32p]-cyclic GMP) and a guanosine triphosphate regenerating system (creatine phosphate 5 retool/l; creatine phosphokinase 11.25 U [E.C. 2.7.3. 
Statistical Analysis
All data are presented as mean + SEM. The statistical comparison between groups with and without glibenclamide and those with varying concentrations of manganese were done by the Student's 't' test for unpaired groups.
Results
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Manganese concentration (mmol/I) Fig. 2 . The effect of varying the manganese concentrations on glibenclamide (at a concentration of 100 nmol/1) enhancement of hepatic guanylate cyclase activity. Varying the concentration of the guanylate cyclase co-factor manganese had no effect on glibenclamide enhancement of guanylate cyclase activity except that a less maximal activation was seen at the 0 versus the higher concentrations of manganese. Each bar is the mean +-SEM of triplicate samples performed on three animals in each group in three separate experiments. [] = without glibenclamide; 9 = with glibenclamide 0.1 mol/l EDTA (pH 7.6) containing about 30000 cpm of [3H]-cyclic GMP (to estimate recovery in the subsequent steps) and then heating at 100 ~ C for 3 min. After cooling in an ice bath, the [32p]cyclic GMP formed was isolated by sequential chromatography on Dowex-AG 50W-X4 H + (200M00 mesh) and alumina using the modification previously described in detail [10] . The overall recovery of cyclic GMP after the two-stage chromatographic procedure was 95%. Blank [32p]-counting rates averaged 40-50 cpm. With
Effect of Glibenclamide on Guanylate Cyclase
Glibenclamide enhanced rat guanylate cyclase activity in a wide variety of tissues (Table 1) . It caused a two-to-threefold enhancement of guanylate cyclase activity in liver, kidney, colon, spleen, pancreas and heart (p < 0.001 for each). The order of maximal responsiveness of guanylate cyclase activity to glibenclamide at a concentration of 1 ~tmol/1 was kidney > heart > colon > spleen > pancreas. The dose-response curve of hepatic guanylate cyclase activity is seen in Figure 1 . More than half-maximal stimulation was observed at concentrations of glibenclamide as low as 10 nmol/1 (p < 0.001). No stimulation of guanylate cyclase was seen when the concentration was decreased to 1 nmol/1. Maximal enhancement was seen at 100 nmol/1 of glibenclamide: no further enhancement was observed increasing the concentration to the ~tmol/1 or mmol/1 range.
Effect of Varying Manganese Concentration on Glibenclamide Enhancement of Guanylate Cyclase
It has recently been reported that certain agents have no effect on guanylate cyclase activity under normal circumstances, but only when the manganese content is absent from the incubation mixture [11] . A series of experiments was performed to determine whether the concentration of guanylate cyclase co-factor manganese affected the glibenclamide activation of guanylate cyclase (Fig.2) . Varying the concentration of manganese had no significant effect on glibenclamide enhancement of guanylate cyclase activity except that decreased maximal activation of the enzyme was seen when manganese was absent from the incubation mixture.
Discussion
In the present investigation, glibenclamide enhanced the activity of guanylate cyclase in a number of peripheral tissues. This enhancement was seen at or below concentrations considered to be in the therapeutic range [6] . There are a number of clinical studies suggesting an extrapancreatic effect of glibenclamide [7, 8] . One of the most recent of these studies [8] demonstrated that, although glibenclamide is known to increase insulin secretion from the pancreas [2-41, there is no response to glibenclamide in vivo unless a meal is also given. This same study revealed that insulin secretion was not significant until 1 h after a combined meal and glibenclamide, but there was a progressive fall in blood glucose which became significant 45 min after glibenclamide administration [8] . These studies suggest that blood glucose can decrease significantly before insulin secretion increases [8] . At the cellular level glibenclamide has recently been shown to increase the number of insulin receptors in vivo in monocytes [5] and in vitro in fibroblasts [6] . Although insulin is known to enhance guanylate cyclase activity in peripheral tissues in diabetic animals [9] , the present investigation in vitro would suggest that glibenclamide can have a direct effect on peripheral tissues without utilizing insulin to mediate its effect.
Evidence against the present findings, being mediated via increased numbers of insulin receptors, is the fact that there was no insulin present in these experiments to cause the enhancement of guanylate cyclase observed. Thus, glibenclamide could not be enhancing the enzyme by causing an increased interaction of insulin with its receptor. It appears, therefore, that glibenclamide may have at least three effects: (1) It increases insulin release from the pancreas [2, 4, 8] , (2) it increases insulin re-271 ceptors in peripheral tissues [5, 6] , and (3) it has a direct effect on at least one enzyme (guanylate cyclase) in peripheral tissues. This last effect is similar to the effect of insulin at the cellular level in diabetic animals in that both exogenous [9] and endogenous [12] insulin increase the activity of the enzyme guanylate cyclase in peripheral tissues to a similar extent as was seen with glibenclamide in the present investigation.
Although the direct benefit of glibenclamide enhancing guanylate cyclase activity to the patient with diabetes cannot be determined from the present investigation in vitro it has been shown previously that the enhancement of guanylate cyclase activity by endogenous insulin is associated with decreased basal hepatic glucose output, gluconeogenesis, and urea production in perfused rat livers [12] . Whether or not cyclic GMP is a 'second messenger' for some aspects of the action of glibenclamide remains to be determined.
Indirect evidence that the effect of glibenclamide on guanylate cyclase activity is not secondary to the decrease in blood glucose induced by the drug is that it takes 30-45 rain for glibenclamide to lower blood glucose significantly [8] , while the present findings were seen at 10 rain. Direct evidence that glucose is not necessary for the effect of glibenclamide on guanylate cyclase activity is that no glucose or sucrose was present during these experiments in vitro. The effects of insulin on guanylate cyclase activity are similarly not secondary to the reduction of blood glucose by insulin. Insulin given in vivo can restore guanylate cyclase activity to control levels (non-diabetic) in 5 rain, a period of time in which there is no decrease in the blood glucose measured in the same animals [9] . Thus, the effect of both insulin and glibenclamide on guanylate cyclase activity in peripheral tissues precedes any reduction in blood glucose.
With regard to cyclic nucleotide metabolism, there appears to be only one other investigation with glibenclamide [13] . In that study, which was performed only on fat cells, the authors concluded that the antilipolytic action of glibenclamide was independent of cyclic AMP levels, although there was some inhibition of the low Km cyclic AMP phosphodiesterase of fat cells [13] . The drug's effects on cyclic GMP metabolism were not studied in that investigation [13] . Other sulphonylureas have been noted to inhibit cyclic AMP phosphodiesterases in peripheral tissues [14] [15] [16] and to increase adenylate cyclase activity in rabbit and human heart [17] . Whether further investigation will reveal an effect of glibenclamide on some aspect of cyclic AMP metabolism remains to be determined, but it should be noted that glibenclamide differs significantly from the older sulphonylureas with the addition of a benzamide radical to the classi-cal benzelsulphonylurea grouping. In diabetic animals, cyclic AMP levels have been noted to be elevated and to decrease to normal (control levels) with insulin treatment [18] . Thus, the increasing of cyclic AMP levels by oral agents would appear more compatible with the deleterious effects of these agents rather than the anti-diabetic effects as suggested previously by Lasseter et al. [17] . Insulin and insulin-like effects, on the other hand, appear to be mediated by the guanylate cyclase-cyclic GMP system [9, 12] . Thus, if glibenclamide were to have insulin-like effects in peripheral tissues one might expect that the guanylate cyclase-cyclic GMP system would be more likely to be involved, as was seen in the present investigation.
Finally, with respect to the mechanism by which glibenclamide interacts with the enzyme guanylate cyclase, it has been reported recently that the guanylate cyclase co-factor manganese may play an important role in the enzyme's interaction with various agents [11] . Superoxide dismutase had no effect on guanylate cyclase activity under normal circumstances but did have an effect when manganese was absent from the incubation mixture [11] . Varying the concentration of manganese had no effect on the enhancement of guanylate cyclase activity in the present investigation. Thus, the stimulation of guanylate cyclase activity by glibenclamide appears to take place with both low and optimal concentrations of the cofactor for the enzyme.
